

# Hongtao Liu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3923427/publications.pdf>

Version: 2024-02-01

60  
papers

1,432  
citations

471509

17  
h-index

361022

35  
g-index

60  
all docs

60  
docs citations

60  
times ranked

2014  
citing authors

#	ARTICLE	IF	CITATIONS
1	Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. <i>Haematologica</i> , 2014, 99, 1373-1379.	3.5	213
2	Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. <i>Blood</i> , 2011, 118, 6438-6445.	1.4	158
3	Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 29.	17.0	146
4	Emerging agents and regimens for AML. <i>Journal of Hematology and Oncology</i> , 2021, 14, 49.	17.0	104
5	Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. <i>Blood</i> , 2021, 137, 3291-3305.	1.4	85
6	The past, present, and future of CRM1/XPO1 inhibitors. <i>Stem Cell Investigation</i> , 2019, 6, 6-6.	3.0	77
7	Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. <i>Blood Advances</i> , 2019, 3, 3488-3498.	5.2	62
8	Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy. , 2019, 7, 175.		59
9	A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2018, 11, 4.	17.0	52
10	Umbilical Cord Blood Transplantation Supported by Third-Party Donor Cells: Rationale, Results, and Applications. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 682-691.	2.0	35
11	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	5.2	35
12	Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. <i>Blood Advances</i> , 2019, 3, 1858-1867.	5.2	25
13	WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia. <i>Experimental Hematology and Oncology</i> , 2018, 7, 1.	5.0	24
14	Immune reconstitution after combined haploidentical and umbilical cord blood transplant. <i>Leukemia and Lymphoma</i> , 2013, 54, 1242-1249.	1.3	23
15	Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant. <i>Experimental Hematology and Oncology</i> , 2019, 8, 1.	5.0	21
16	Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1065-1072.	2.0	20
17	Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 359-365.	2.0	20
18	Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1025-1027.	2.0	20

#	ARTICLE	IF	CITATIONS
19	Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 997-1004.	2.0	18
20	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	5.2	18
21	Novel strategies for immuno-oncology breakthroughs with cell therapy. <i>Biomarker Research</i> , 2021, 9, 62.	6.8	18
22	Preliminary Results of Balli-01: A Phase I Study of UCART22 (allogeneic engineered T-cells expressing) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Acute Lymphoblastic Leukemia (B-ALL). <i>Blood</i> , 2020, 136, 7-8.	1.4	15
23	No Exit: Identifying Avoidable Terminal Oncology Intensive Care Unit Hospitalizations. <i>Journal of Oncology Practice</i> , 2016, 12, e901-e911.	2.5	13
24	Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 34-42.	1.2	13
25	Expanded indications for allogeneic stem cell transplantation in patients with myeloid malignancies. <i>Current Opinion in Hematology</i> , 2013, 20, 115-122.	2.5	11
26	Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. <i>Bone Marrow Transplantation</i> , 2020, 55, 1161-1168.	2.4	11
27	Pembrolizumab for the Treatment of Disease Relapse Following Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 3415-3415.	1.4	11
28	A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-Cell Malignancies. <i>Blood</i> , 2021, 138, 3868-3868.	1.4	11
29	Alternative Donor Transplantationâ€”â€œMixing and Matchingâ€”the Role of Combined Cord Blood and Haplo-Identical Donor Transplantation (Haplo-Cord SCT) as a Treatment Strategy for Patients Lacking Standard Donors?. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 1-7.	2.3	10
30	Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. <i>Journal of Geriatric Oncology</i> , 2021, 12, 585-591.	1.0	10
31	Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. <i>Leukemia and Lymphoma</i> , 2016, 57, 1807-1813.	1.3	9
32	A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 599-606.	5.2	9
33	A 2:1 randomized, open-label, phase II study of selinexor vs. physicianâ€™s choice in older patients with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-12.	1.3	9
34	Reduction of Imatinib Concentration After Gastric Bypass Surgery. <i>Blood</i> , 2010, 116, 4948-4948.	1.4	9
35	Preliminary Results from the Flu/Cy/Alemtuzumab Arm of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL). <i>Blood</i> , 2021, 138, 1746-1746.	1.4	9
36	Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2020, 55, 2204-2206.	2.4	5

#	ARTICLE	IF	CITATIONS
37	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>t(8;21) KMT2A</i> -rearranged AML. <i>Blood Advances</i> , 2022, 6, 828-847.	5.2	5
38	A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies. <i>Scientific Reports</i> , 2021, 11, 22355.	3.3	5
39	Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 629-638.	1.3	4
40	Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. <i>EJHaem</i> , 2021, 2, 413-420.	1.0	4
41	Haplo-Cord UCB SCT with Low Cell Dose, Well Matched UCB Units. a Prospective Multicenter Study. <i>Blood</i> , 2014, 124, 1093-1093.	1.4	4
42	Geriatric Assessment (GA) to Predict Survival in Older Allogeneic Hematopoietic Cell Transplantation (HCT) Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S39-S40.	2.0	3
43	Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors. <i>Blood</i> , 2019, 134, 4176-4176.	1.4	3
44	Efficacy of Single-Agent Decitabine in Relapsed and Primary Refractory (rel/ref) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 2518-2518.	1.4	3
45	A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. <i>Blood Advances</i> , 0, , .	5.2	3
46	Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 1956-1956.	1.4	2
47	Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results. <i>Blood</i> , 2020, 136, 41-42.	1.4	2
48	The Outcomes of Second Allogeneic Stem Cell Transplantation for Disease Relapse after T Cell Depleted Allogeneic Stem Cell Transplantation: A Single Center Experience-University of Chicago. <i>Blood</i> , 2014, 124, 2509-2509.	1.4	2
49	Is it time to use minimal residual disease to stratify post-remission treatment for acute myeloid leukemia?. <i>Leukemia and Lymphoma</i> , 2015, 56, 3005-3007.	1.3	1
50	Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. <i>Leukemia and Lymphoma</i> , 2021, 62, 1497-1501.	1.3	1
51	WT1 Peptide Vaccine Is Able to Induce WT1-Specific Immune Response with TCR Clonal Enrichment to Control Minimal Residual Disease in Patients with Myeloid Leukemia. <i>Blood</i> , 2016, 128, 3984-3984.	1.4	1
52	Comorbidity from Solid Tumor or Hematologic Malignancy Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) May Both Increase Non-Relapse Mortality. <i>Blood</i> , 2016, 128, 5844-5844.	1.4	1
53	A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes. <i>Blood</i> , 2011, 118, 496-496.	1.4	0
54	Frequency and Risk Factors of Cord Graft Failure (CGF) Following Reduced Intensity Conditioning Haplo-Cord Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 2463-2463.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Incidence and Predictors of Respiratory Viral Infections By Multi-Plex PCR in Allogeneic Hematopoietic Cell Transplant (HCT) Recipients 50 Years and Older Including Geriatric Assessment (GA). Blood, 2014, 124, 2464-2464.	1.4	0
56	Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML). Blood, 2015, 126, 3777-3777.	1.4	0
57	Evaluation of a pre-transplant serum biomarker score for allogeneic hematopoietic stem cell transplant (HCT) and association with clinical factors.. Journal of Clinical Oncology, 2016, 34, e18537-e18537.	1.6	0
58	Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML). Blood, 2018, 132, 4073-4073.	1.4	0
59	Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS. Blood, 2019, 134, 3324-3324.	1.4	0
60	Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT). Blood, 2020, 136, 39-40.	1.4	0